Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2

NCT02059759 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Nīmes as lead sponsor.

NCT NCT02059759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02059759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2
Lead sponsor
Centre Hospitalier Universitaire de Nīmes
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2015
Completion date
May 25, 2016
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis